A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer
1996

Study of ECF Chemotherapy in Pancreatic Cancer

Sample size: 35 publication Evidence: moderate

Author Information

Author(s): TRJ Evans, FJ Lofts, JL Mansil, JP Glees, AG Dalgleish, MJ Knight

Primary Institution: St George's Hospital Medical School

Hypothesis

The ECF regimen can improve survival in patients with inoperable pancreatic cancer.

Conclusion

The ECF regimen can prolong survival in patients with locally advanced or metastatic pancreatic cancer, but it is associated with considerable toxicity.

Supporting Evidence

  • Objective tumour responses were documented in five (17.3%) patients.
  • Patients with stable disease or partial response had a median survival of 253 days.
  • Grade 3/4 toxicity included alopecia in 56% of patients and neutropenic sepsis in 10 patients.

Takeaway

This study tested a new chemotherapy combination for pancreatic cancer and found it can help some patients live longer, but it can also cause serious side effects.

Methodology

Patients with inoperable pancreatic cancer received continuous infusion of 5-FU, cisplatin, and epirubicin, and their responses and toxicities were evaluated.

Potential Biases

Potential bias due to lack of randomization and the observational nature of the study.

Limitations

The study had a small sample size and high toxicity rates, which may limit the generalizability of the results.

Participant Demographics

Mean age was 59 years, with a range of 37-75 years; 21 males and 14 females.

Statistical Information

P-Value

0.01

Statistical Significance

p=0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication